Last reviewed · How we verify
NCT05274867: PROM-OSP
Development of a Patient Reported Outcome Measure for Advanced Ovarian Cancer Patients Receiving Surgical and Chemotherapy Treatment
trial in Ovarian Cancer in 137 participants. Status unknown.
7 June 2022
Quick facts
| Lead sponsor | The Christie NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 137 |
| Start date | 7 March 2022 |
| Primary completion | 7 June 2022 |
| Estimated completion | 7 June 2022 |
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Surgery — all drugs for Surgery →
- Chemotherapy — all drugs for Chemotherapy →
- Patient Reported Outcome Measure — all drugs for Patient Reported Outcome Measure →
Sponsor
The Christie NHS Foundation Trust
Who can join
18 and older, female only, with Ovarian Cancer or Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Development of a patient reported outcome measure (PROM) for ovarian cancer patients receiving combined surgery and radiotherapy
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05274867
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other The Christie NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07183267 — Using Red Light Therapy to Ease Skin Side Effects and Mouth Side Effects, in Children and Young People Aged 0 to 16 Year · NA · not yet recruiting
- NCT07268339 — A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calme · Phase 3 · not yet recruiting
- NCT06965101 — To Determine Whether it is Feasible to Treat Patients Requiring Urgent Radiotherapy Diagnosed With Metastatic Cord Compr · NA · recruiting
- NCT05903430 — A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION) · recruiting
- NCT07202260 — Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05274867 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Christie NHS Foundation Trust
- Last refreshed: 11 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05274867.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing